Trial Profile
Apatinib plus Docetaxel for Treating Taxol Resistant Patients with Ovarian Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Jun 2017
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Rivoceranib (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- 13 Jun 2017 New trial record